Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase II Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of 4 Different Regimens of MK-7009 When Administered Concomitantly With Pegylated Interferon and Ribavirin in Treatment-Experienced Patients With Chronic Genotype 1 Hepatitis C Virus Infection
Brief Summary: The purpose of this study is to test the safety, tolerability, and efficacy of 4 regimens of Vaniprevir + Peg-IFN and Ribavirin as compared to Placebo (PBO) + Peg-IFN/RBV. The primary hypotheses are that Vaniprevir is well tolerated, and that Vaniprevir 600 mg twice daily (b.i.d.) is superior to the control regimen for the percentage of non-cirrhotic (NC) participants achieving undetectable HCV ribonucleic acid (RNA) 24 weeks after the end of study therapy (SVR24).


Options:
A: Arm Label: 24-wk Vaniprevir 600 mg + Peg-IFN/RBV; Type: EXPERIMENTAL; Interventions: Drug: Vaniprevir, Drug: Pegylated Interferon (Peg-IFN), Drug: Ribavirin (RBV) | Arm Label: 24-wk Vaniprevir 600 mg + 24-wk PBO + Peg-IFN/RBV; Type: EXPERIMENTAL; Interventions: Drug: Vaniprevir, Drug: Pegylated Interferon (Peg-IFN), Drug: Ribavirin (RBV), Drug: Placebo (PBO) | Arm Label: 48-wk Vaniprevir 300 mg + Peg-IFN/RBV; Type: EXPERIMENTAL; Interventions: Drug: Vaniprevir, Drug: Pegylated Interferon (Peg-IFN), Drug: Ribavirin (RBV) | Arm Label: 48-wk Vaniprevir 600 mg + Peg-IFN/RBV; Type: EXPERIMENTAL; Interventions: Drug: Vaniprevir, Drug: Pegylated Interferon (Peg-IFN), Drug: Ribavirin (RBV) | Arm Label: 48-wk PBO + Peg-IFN/RBV; Type: PLACEBO_COMPARATOR; Interventions: Drug: Pegylated Interferon (Peg-IFN), Drug: Ribavirin (RBV), Drug: Placebo (PBO) | Intervention Type: DRUG; Name: Vaniprevir; Assigned to Arm(s): 24-wk Vaniprevir 600 mg + 24-wk PBO + Peg-IFN/RBV, 24-wk Vaniprevir 600 mg + Peg-IFN/RBV, 48-wk Vaniprevir 300 mg + Peg-IFN/RBV, 48-wk Vaniprevir 600 mg + Peg-IFN/RBV | Intervention Type: DRUG; Name: Pegylated Interferon (Peg-IFN); Assigned to Arm(s): 24-wk Vaniprevir 600 mg + 24-wk PBO + Peg-IFN/RBV, 24-wk Vaniprevir 600 mg + Peg-IFN/RBV, 48-wk PBO + Peg-IFN/RBV, 48-wk Vaniprevir 300 mg + Peg-IFN/RBV, 48-wk Vaniprevir 600 mg + Peg-IFN/RBV | Intervention Type: DRUG; Name: Ribavirin (RBV); Assigned to Arm(s): 24-wk Vaniprevir 600 mg + 24-wk PBO + Peg-IFN/RBV, 24-wk Vaniprevir 600 mg + Peg-IFN/RBV, 48-wk PBO + Peg-IFN/RBV, 48-wk Vaniprevir 300 mg + Peg-IFN/RBV, 48-wk Vaniprevir 600 mg + Peg-IFN/RBV | Intervention Type: DRUG; Name: Placebo (PBO); Assigned to Arm(s): 24-wk Vaniprevir 600 mg + 24-wk PBO + Peg-IFN/RBV, 48-wk PBO + Peg-IFN/RBV
B: Arm Label: Daclatasvir plus peg-interferon alfa-2a and ribavirin (20 mg); Type: EXPERIMENTAL; Interventions: Drug: Daclatasvir, Drug: peg-interferon alfa-2a, Drug: ribavirin | Arm Label: Daclatasvir plus peg-interferon alfa-2a and ribavirin (60 mg); Type: EXPERIMENTAL; Interventions: Drug: Daclatasvir, Drug: peg-interferon alfa-2a, Drug: ribavirin | Arm Label: Placebo plus peg-interferon alfa-2a and ribavirin; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: peg-interferon alfa-2a, Drug: ribavirin | Intervention Type: DRUG; Name: Daclatasvir; Assigned to Arm(s): Daclatasvir plus peg-interferon alfa-2a and ribavirin (20 mg) | Intervention Type: DRUG; Name: Daclatasvir; Assigned to Arm(s): Daclatasvir plus peg-interferon alfa-2a and ribavirin (60 mg) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo plus peg-interferon alfa-2a and ribavirin | Intervention Type: DRUG; Name: peg-interferon alfa-2a; Assigned to Arm(s): Daclatasvir plus peg-interferon alfa-2a and ribavirin (20 mg), Daclatasvir plus peg-interferon alfa-2a and ribavirin (60 mg), Placebo plus peg-interferon alfa-2a and ribavirin | Intervention Type: DRUG; Name: ribavirin; Assigned to Arm(s): Daclatasvir plus peg-interferon alfa-2a and ribavirin (20 mg), Daclatasvir plus peg-interferon alfa-2a and ribavirin (60 mg), Placebo plus peg-interferon alfa-2a and ribavirin
C: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Drug: TMC435, Drug: PSI-7977 (GS7977), Drug: Ribavirin | Arm Label: Arm 2; Type: EXPERIMENTAL; Interventions: Drug: TMC435, Drug: PSI-7977 (GS7977) | Arm Label: Arm 3; Type: EXPERIMENTAL; Interventions: Drug: TMC435, Drug: PSI-7977 (GS7977), Drug: Ribavirin | Arm Label: Arm 4; Type: EXPERIMENTAL; Interventions: Drug: TMC435, Drug: PSI-7977 (GS7977) | Intervention Type: DRUG; Name: TMC435; Assigned to Arm(s): Arm 1, Arm 2, Arm 3, Arm 4 | Intervention Type: DRUG; Name: PSI-7977 (GS7977); Assigned to Arm(s): Arm 1, Arm 2, Arm 3, Arm 4 | Intervention Type: DRUG; Name: Ribavirin; Assigned to Arm(s): Arm 1, Arm 3
D: Arm Label: Group 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Daclatasvir, Drug: Placebo | Arm Label: Group 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Daclatasvir, Drug: Placebo | Arm Label: Group 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: Daclatasvir, Drug: Placebo | Arm Label: Group 4; Type: ACTIVE_COMPARATOR; Interventions: Drug: Daclatasvir, Drug: Placebo | Arm Label: Group 5; Type: ACTIVE_COMPARATOR; Interventions: Drug: Daclatasvir, Drug: Placebo | Arm Label: Group 6; Type: ACTIVE_COMPARATOR; Interventions: Drug: Daclatasvir, Drug: Placebo | Intervention Type: DRUG; Name: Daclatasvir; Assigned to Arm(s): Group 1, Group 2, Group 3, Group 4, Group 5, Group 6 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Group 1, Group 2, Group 3, Group 4, Group 5, Group 6

Answer: A